Sorry, Shkreli: Supreme Court rebuffs ex-pharma CEO's final appeal

shkreli
The U.S. Supreme Court refused to hear former Retrophin CEO Martin Shkreli's appeal to overrun his 2017 fraud conviction. (Getty)

Martin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS Hail Mary after multiple appeals fell flat. Turns out the court wasn't interested in hearing Shkreli's pleas at all. 

The U.S. Supreme Court on Monday denied hearing Shkreli's appeal to overturn his 2017 fraud conviction after his disastrous run as head of biotech Retrophin. Shkreli was also forced to forfeit $7.36 million in his conviction.

With that final rebuff, Shkreli will likely see the inside of a jail cell for the next five years––a sentence that could grow longer after he was accused of running his business from behind bars. 

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

RELATED: Shkreli's jail-cell business dealings draw scrutiny from the feds: WSJ

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.